Evidence map›Paper›PMID 35315885›Full record

Trial reportJAMA2022

Prophylactic Oral Dextrose Gel and Neurosensory Impairment at 2-Year Follow-up of Participants in the hPOD Randomized Trial.

Taygen Edwards, Jane M Alsweiler, Caroline A Crowther, Richard Edlin, Greg D Gamble, Joanne E Hegarty, Luling Lin, Christopher J D McKinlay, Jenny A Rogers, Benjamin Thompson and 2 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in JAMA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Oral dextrose gel to prevent hypoglycaemia in at-risk neonates.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Prophylactic dextrose gel use in newborns at risk for hypoglycemia.Journal of perinatology : official journal of the California Perinatal Association · 2024
    Observational
  12. Neonatal hypoglycaemia.BMJ medicine · 2024
    Review
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Taygen EdwardsLiggins Institute, University of Auckland, Auckland, New Zealand.
Jane M AlsweilerDepartment of Paediatrics: Child and Youth Health, University of Auckland, Auckland, New Zealand.
Caroline A CrowtherLiggins Institute, University of Auckland, Auckland, New Zealand.
Richard EdlinHealth Systems, School of Population Health, University of Auckland, Auckland, New Zealand.
Greg D GambleLiggins Institute, University of Auckland, Auckland, New Zealand.
Joanne E HegartyNewborn Services, Auckland City Hospital, Auckland, New Zealand.
Luling LinLiggins Institute, University of Auckland, Auckland, New Zealand.
Christopher J D McKinlayLiggins Institute, University of Auckland, Auckland, New Zealand.
Jenny A RogersLiggins Institute, University of Auckland, Auckland, New Zealand.
Benjamin ThompsonSchool of Optometry and Vision Science, Waterloo, Ontario, Canada.
Trecia A WouldesDepartment of Psychological Medicine, University of Auckland, Auckland, New Zealand.
Jane E HardingLiggins Institute, University of Auckland, Auckland, New Zealand.
University of Auckland · NZAuckland City Hospital · NZ

Funding

"Two year outcomes after dextrose gel prophylaxis for neonatal hypoglycaemia"R01HD091075 · NICHD · UNIVERSITY OF AUCKLAND · PI HARDING, JANE · 2018 to 2022
$2.0M
NICHD NIH HHS R01 HD091075
6 · The paper itself

Abstract

Importance: Prophylactic oral dextrose gel reduces neonatal hypoglycemia, but later benefits or harms remain unclear. Objective: To assess the effects on later development of prophylactic dextrose gel for infants born at risk of neonatal hypoglycemia. Design, Setting, and Participants: Prospective follow-up of a multicenter randomized clinical trial conducted in 18 Australian and New Zealand hospitals from January 2015 to May 2019. Participants were late preterm or term at-risk infants; those randomized in 9 New Zealand centers (n = 1359) were included and followed up between January 2017 and July 2021. Interventions: Infants were randomized to prophylactic 40% dextrose (n = 681) or placebo (n = 678) gel, 0.5 mL/kg, massaged into the buccal mucosa 1 hour after birth. Main Outcomes and Measures: The primary outcome of this follow-up study was neurosensory impairment at 2 years' corrected age. There were 44 secondary outcomes, including cognitive, language, and motor composite Bayley-III scores (mean [SD], 100 [15]; higher scores indicate better performance). Results: Of eligible infants, 1197 (91%) were assessed (581 females [49%]). Neurosensory impairment was not significantly different between the dextrose and placebo gel groups (20.8% vs 18.7%; unadjusted risk difference [RD], 2.09% [95% CI, -2.43% to 6.60%]; adjusted risk ratio [aRR], 1.13 [95% CI, 0.90 to 1.41]). The risk of cognitive and language delay was not significantly different between the dextrose and placebo groups (cognitive: 7.6% vs 5.3%; RD, 2.32% [95% CI, -0.46% to 5.11%]; aRR, 1.40 [95% CI, 0.91 to 2.17]; language: 17.0% vs 14.7%; RD, 2.35% [95% CI, -1.80% to 6.50%]; aRR, 1.19 [95% CI, 0.92 to 1.54]). However, the dextrose gel group had a significantly higher risk of motor delay (2.5% vs 0.7%; RD, 1.81% [95% CI, 0.40% to 3.23%]; aRR, 3.79 [95% CI, 1.27 to 11.32]) and significantly lower composite scores for cognitive (adjusted mean difference [aMD], -1.30 [95% CI, -2.55 to -0.05]), language (aMD, -2.16 [95% CI, -3.86 to -0.46]), and motor (aMD, -1.40 [95% CI, -2.60 to -0.20]) performance. There were no significant differences between groups in the other 27 secondary outcomes. Conclusions and Relevance: Among late preterm and term infants born at risk of neonatal hypoglycemia, prophylactic oral 40% dextrose gel at 1 hour of age, compared with placebo, resulted in no significant difference in the risk of neurosensory impairment at 2 years' corrected age. However, the study may have been underpowered to detect a small but potentially clinically important increase in risk, and further research including longer-term follow-up is required. Trial Registration: anzctr.org.au Identifier: ACTRN12614001263684.

Indexed as

Administration, OralChemopreventionChild, PreschoolDouble-Blind MethodFemaleFollow-Up StudiesGelsGlucoseHumansHypoglycemiaInfant, NewbornMaleProspective StudiesSensation DisordersTime FactorsGelsGlucose

Identifiers

PMID35315885
PMCPMC8941358
OpenAlexW4221055344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.